- Else (BABY) has received Institutional Review Board (IRB) approval for its infant growth clinical study protocol
- This is a key step toward the U.S. launch of Else’s new plant-based infant formula, which will serve as an alternative to dairy and soy-based products
- CEO Hamutal Yitzhak spoke with Coreena Robertson about the news
- Else is developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children and adults
- Else Nutrition (BABY) is up by 2.99 per cent trading at $0.69 per share
Else Nutrition (BABY) has received IRB approval for its infant growth clinical study protocol.
The clinical study will provide vital insights into the formula’s effectiveness and safety for infants.
This is a critical step in the company’s plan to launch a new plant-based infant formula in the U.S. as an alternative to dairy and soy-based products.
CEO Hamutal Yitzhak spoke with Coreena Robertson about the news.
Else is developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children and adults.
Else Nutrition (BABY) is up by 2.99 per cent trading at $0.69 per share as of 9:44 am EST.
Latest News
-
Newsfile March 13, 2025
-
Newsfile March 4, 2025
-
Newsfile February 25, 2025
-
Newsfile January 28, 2025
-
Newsfile December 30, 2024
-
Newsfile December 18, 2024
Latest Bullboard Posts
-
Recent Trades - All 8 today More trades... ...2 weeks ago
-
LOL Redheaded stepchild ! good one Reddog11 ! Yeah i watched about 25 mins of...2 weeks ago
-
CCMI AGM April 29 2025 Calgary should be interesting2 weeks ago
-
Well Ian is already giving interviews for Lion One. Starts at about 22 minutes...2 weeks ago
-
Thanks GD! appreciate that.. eomMarch 24, 2025
-
I fully agree with everything you've written. Ian has lulled us to sleep...March 24, 2025
